Literature DB >> 29282220

Inflammasome Adaptor ASC Suppresses Apoptosis of Gastric Cancer Cells by an IL18-Mediated Inflammation-Independent Mechanism.

Virginie Deswaerte1,2, Paul Nguyen3,4, Alison West1,2, Alison F Browning1,2, Liang Yu1,2, Saleela M Ruwanpura1,2, Jesse Balic1,2, Thaleia Livis1,2, Charlotte Girard5,6, Adele Preaudet3,4, Hiroko Oshima7, Ka Yee Fung3,4, Hazel Tye1,2, Meri Najdovska1,2, Matthias Ernst8, Masanobu Oshima7, Cem Gabay5,6, Tracy Putoczki3,4, Brendan J Jenkins9,2.   

Abstract

Inflammasomes are key regulators of innate immunity in chronic inflammatory disorders and autoimmune diseases, but their role in inflammation-associated tumorigenesis remains ill-defined. Here we reveal a protumorigenic role in gastric cancer for the key inflammasome adaptor apoptosis-related speck-like protein containing a CARD (ASC) and its effector cytokine IL18. Genetic ablation of ASC in the gp130F/F spontaneous mouse model of intestinal-type gastric cancer suppressed tumorigenesis by augmenting caspase-8-like apoptosis in the gastric epithelium, independently from effects on myeloid cells and mucosal inflammation. This phenotype was characterized by reduced activation of caspase-1 and NF-κB activation and reduced expression of mature IL18, but not IL1β, in gastric tumors. Genetic ablation of IL18 in the same model also suppressed gastric tumorigenesis, whereas blockade of IL1β and IL1α activity upon genetic ablation of the IL1 receptor had no effect. The specific protumorigenic role for IL18 was associated with high IL18 gene expression in the gastric tumor epithelium compared with IL1β, which was preferentially expressed in immune cells. Supporting an epithelial-specific role for IL18, we found it to be highly secreted from human gastric cancer cell lines. Moreover, IL18 blockade either by a neutralizing anti-IL18 antibody or by CRISPR/Cas9-driven deletion of ASC augmented apoptosis in human gastric cancer cells. In clinical specimens of human gastric cancer tumors, we observed a significant positive correlation between elevated mature IL18 protein and ASC mRNA levels. Collectively, our findings reveal the ASC/IL18 signaling axis as a candidate therapeutic target in gastric cancer.Significance: Inflammasome activation that elevates IL18 helps drive gastric cancer by protecting cancer cells against apoptosis, with potential implications for new therapeutic strategies in this setting. Cancer Res; 78(5); 1293-307. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29282220     DOI: 10.1158/0008-5472.CAN-17-1887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Cross-talk between IL-6 trans-signaling and AIM2 inflammasome/IL-1β axes bridge innate immunity and epithelial apoptosis to promote emphysema.

Authors:  Saleela M Ruwanpura; Louise McLeod; Lovisa F Dousha; Huei J Seow; Alison C West; Alice J West; Teresa Weng; Mohammad Alanazi; Martin MacDonald; Paul T King; Philip G Bardin; Cem Gabay; Dennis M Klinman; Steven Bozinovski; Ross Vlahos; Gary P Anderson; Stefan Rose-John; Mohamed I Saad; Brendan J Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

Review 2.  Context-dependent functions of pattern recognition receptors in cancer.

Authors:  Si Ming Man; Brendan J Jenkins
Journal:  Nat Rev Cancer       Date:  2022-03-30       Impact factor: 69.800

3.  Identification of Key Pyroptosis-Related Genes and Distinct Pyroptosis-Related Clusters in Periodontitis.

Authors:  Wanchen Ning; Aneesha Acharya; Simin Li; Gerhard Schmalz; Shaohong Huang
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 4.  Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.

Authors:  Weitong Gao; Xueying Wang; Yang Zhou; Xueqian Wang; Yan Yu
Journal:  Signal Transduct Target Ther       Date:  2022-06-20

Review 5.  Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis.

Authors:  Qing Bi; Ji-Yue Wu; Xue-Meng Qiu; Jian-Dong Zhang; Ze-Jia Sun; Wei Wang
Journal:  J Immunol Res       Date:  2022-06-13       Impact factor: 4.493

Review 6.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

Review 7.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

Review 8.  Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy.

Authors:  Xiaomin Liu; Yang Shao; Jinbao Zhou; Guangren Qian; Zhongliang Ma
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-18       Impact factor: 8.886

9.  A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma.

Authors:  Chenhao Zhou; Shun Wang; Qiang Zhou; Jin Zhao; Xianghou Xia; Wanyong Chen; Yan Zheng; Min Xue; Feng Yang; Deliang Fu; Yirui Yin; Manar Atyah; Lunxiu Qin; Yue Zhao; Christiane Bruns; Huliang Jia; Ning Ren; Qiongzhu Dong
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

Review 10.  The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer.

Authors:  Man Wang; Shuai Jiang; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.